These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 31921219)

  • 1. Combination of STING Pathway Agonist With Saponin Is an Effective Adjuvant in Immunosenescent Mice.
    Vassilieva EV; Taylor DW; Compans RW
    Front Immunol; 2019; 10():3006. PubMed ID: 31921219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. cGAMP/Saponin Adjuvant Combination Improves Protective Response to Influenza Vaccination by Microneedle Patch in an Aged Mouse Model.
    Vassilieva EV; Li S; Korniychuk H; Taylor DM; Wang S; Prausnitz MR; Compans RW
    Front Immunol; 2020; 11():583251. PubMed ID: 33603732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancing Immune Response and Heterosubtypic Protection Ability of Inactivated H7N9 Vaccine by Using STING Agonist as a Mucosal Adjuvant.
    Luo J; Liu XP; Xiong FF; Gao FX; Yi YL; Zhang M; Chen Z; Tan WS
    Front Immunol; 2019; 10():2274. PubMed ID: 31611875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
    Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
    Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Synthetic Dual Agonistic Liposomal TLR4/7 Adjuvant Promotes Broad Immune Responses in an Influenza Vaccine With Minimal Reactogenicity.
    Sato-Kaneko F; Yao S; Lao FS; Shpigelman J; Messer K; Pu M; Shukla NM; Cottam HB; Chan M; Chu PJ; Burkhart D; Schoener R; Matsutani T; Carson DA; Corr M; Hayashi T
    Front Immunol; 2020; 11():1207. PubMed ID: 32636840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved Immune Responses in Young and Aged Mice with Adjuvanted Vaccines against H1N1 Influenza Infection.
    Baldwin SL; Hsu FC; Van Hoeven N; Gage E; Granger B; Guderian JA; Larsen SE; Lorenzo EC; Haynes L; Reed SG; Coler RN
    Front Immunol; 2018; 9():295. PubMed ID: 29515589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
    Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inactivated Eyedrop Influenza Vaccine Adjuvanted with Poly(I:C) Is Safe and Effective for Inducing Protective Systemic and Mucosal Immunity.
    Kim ED; Han SJ; Byun YH; Yoon SC; Choi KS; Seong BL; Seo KY
    PLoS One; 2015; 10(9):e0137608. PubMed ID: 26355295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung.
    Neuhaus V; Chichester JA; Ebensen T; Schwarz K; Hartman CE; Shoji Y; Guzmán CA; Yusibov V; Sewald K; Braun A
    Vaccine; 2014 May; 32(26):3216-22. PubMed ID: 24731807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant.
    Beljanski V; Chiang C; Kirchenbaum GA; Olagnier D; Bloom CE; Wong T; Haddad EK; Trautmann L; Ross TM; Hiscott J
    J Virol; 2015 Oct; 89(20):10612-24. PubMed ID: 26269188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mannan adjuvants intranasally administered inactivated influenza virus in mice rendering low doses inductive of strong serum IgG and IgA in the lung.
    Proudfoot O; Esparon S; Tang CK; Laurie K; Barr I; Pietersz G
    BMC Infect Dis; 2015 Feb; 15():101. PubMed ID: 25887952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of the Microparticle Nanoscale Silicon Dioxide as an Adjuvant To Boost Vaccine Immune Responses against Influenza Virus in Neonatal Mice.
    Russell RF; McDonald JU; Lambert L; Tregoning JS
    J Virol; 2016 May; 90(9):4735-4744. PubMed ID: 26912628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary surfactant-biomimetic nanoparticles potentiate heterosubtypic influenza immunity.
    Wang J; Li P; Yu Y; Fu Y; Jiang H; Lu M; Sun Z; Jiang S; Lu L; Wu MX
    Science; 2020 Feb; 367(6480):. PubMed ID: 32079747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
    de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
    Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcium phosphate nanoparticle (CaPNP) for dose-sparing of inactivated whole virus pandemic influenza A (H1N1) 2009 vaccine in mice.
    Morçӧl T; Hurst BL; Tarbet EB
    Vaccine; 2017 Aug; 35(35 Pt B):4569-4577. PubMed ID: 28716554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influenza virosomes supplemented with GPI-0100 adjuvant: a potent vaccine formulation for antigen dose sparing.
    Liu H; de Vries-Idema J; Ter Veer W; Wilschut J; Huckriede A
    Med Microbiol Immunol; 2014 Feb; 203(1):47-55. PubMed ID: 24062182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Murine Cross-Reactive Nonneutralizing Polyclonal IgG1 Antibodies Induced by Influenza Vaccine Inhibit the Cross-Protective Effect of IgG2 against Heterologous Virus in Mice.
    Shibuya M; Aoshi T; Kuroda E; Yoshioka Y
    J Virol; 2020 Jun; 94(12):. PubMed ID: 32269125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical evaluation of the saponin derivative GPI-0100 as an immunostimulating and dose-sparing adjuvant for pandemic influenza vaccines.
    Liu H; Bungener L; ter Veer W; Coller BA; Wilschut J; Huckriede A
    Vaccine; 2011 Mar; 29(11):2037-43. PubMed ID: 21251903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral immunization of haemaggulutinin H5 expressed in plant endoplasmic reticulum with adjuvant saponin protects mice against highly pathogenic avian influenza A virus infection.
    Lee G; Na YJ; Yang BG; Choi JP; Seo YB; Hong CP; Yun CH; Kim DH; Sohn EJ; Kim JH; Sung YC; Kim YK; Jang MH; Hwang I
    Plant Biotechnol J; 2015 Jan; 13(1):62-72. PubMed ID: 25065685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.